Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Pennsylvania: - Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
- Chambersburg Hospital — Chambersburg, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- Geisinger Cancer Center Dickson City — Dickson City, Pennsylvania
- Ephrata Cancer Center — Ephrata, Pennsylvania
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Bryn Mawr Hospital — Bryn Mawr, Pennsylvania
- Pocono Medical Center — East Stroudsburg, Pennsylvania
- UPMC Hillman Cancer Center Erie — Erie, Pennsylvania
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Pennsylvania: - Local Institution - Unk041 — Allentown, Pennsylvania
- Veterans Affairs Pittsburgh Healthcare System - University Drive Campus — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …
Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Pennsylvania: - USO - Alliance Cancer Specialists, PC — Horsham, Pennsylvania
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office — Philadelphia, Pennsylvania
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Pennsylvania: - Clinical Study Site — Philadelphia, Pennsylvania
- Clinical Study Site — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable gen…
Sponsor: AstraZeneca
NCT ID: NCT07291037
Sites in Pennsylvania: - Research Site — Hershey, Pennsylvania
- Research Site — Lancaster, Pennsylvania
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Pennsylvania: - St. Lukes Hospital and Health Network ( Site 0186) — Bethlehem, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Pennsylvania: - Lancaster General Hospital - Ann B Barshinger Cancer Institute — Lancaster, Pennsylvania
- Local Institution - 0504 — Philadelphia, Pennsylvania
Phase 3 Recruiting Industry
The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/…
Sponsor: OncoC4, Inc.
NCT ID: NCT05671510
Sites in Pennsylvania: - St. Luke's University Health Network - 1179 — Bethlehem, Pennsylvania
- Donald Guthrie Foundation - 1135 — Sayre, Pennsylvania
- Cancer Care Associates of York, Inc. - 1113 — York, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Pennsylvania: - Hospital of the University of Pennsylvania (Adults only) — Philadelphia, Pennsylvania
- The Children's Hospital of Philadelphia Oncology Division, Blood & Marrow Transplant Section (Pediatrics) — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center (Adults only) — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (E…
Sponsor: Gilead Sciences
NCT ID: NCT06801834
Sites in Pennsylvania: - Spoknwrd Clinical Trials Inc. — Easton, Pennsylvania
Phase 3 Recruiting Industry
This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of meta…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06422143
Sites in Pennsylvania: - St Luke's University Health Network ( Site 0017) — Bethlehem, Pennsylvania
- Thomas Jefferson University - Clinical Research Institute ( Site 0147) — Philadelphia, Pennsylvania
Phase 2, Phase 3 Recruiting Industry
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and ef…
Sponsor: AbbVie
NCT ID: NCT06236438
Sites in Pennsylvania: - Guthrie Robert Packer Hospital /ID# 262758 — Sayre, Pennsylvania
Phase 3 Recruiting Industry
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Sites in Pennsylvania: - Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134) — Lancaster, Pennsylvania
Phase 3 Recruiting Industry
Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The g…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07190248
Sites in Pennsylvania: - Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111) — Lancaster, Pennsylvania
Phase 3 Recruiting Industry
This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging …
Sponsor: Vergent Bioscience, Inc.
NCT ID: NCT07499674
Sites in Pennsylvania: - Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Pennsylvania: - UPMC Altoona — Altoona, Pennsylvania
- UPMC-Heritage Valley Health System Beaver — Beaver, Pennsylvania
- UPMC Hillman Cancer Center at Butler Health System — Butler, Pennsylvania
- Carlisle Regional Cancer Center — Carlisle, Pennsylvania
- WellSpan Medical Oncology and Hematology — Chambersburg, Pennsylvania
Phase 2 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…
Sponsor: AbbVie
NCT ID: NCT06568939
Sites in Pennsylvania: - Guthrie Robert Packer Hospital /ID# 270316 — Sayre, Pennsylvania
- Cancer Care Associates Of York /ID# 270971 — York, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Pennsylvania: - USOR Alliance Cancer Specialist — Doylestown, Pennsylvania
- Allegheny Health Network — Pittsburgh, Pennsylvania
Phase 2 Recruiting NIH
This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation therapy followed by durvalumab works better than the usual care trea…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05198830
Sites in Pennsylvania: - University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a…
Sponsor: Synthekine
NCT ID: NCT05098132
Sites in Pennsylvania: - Fox Chase Cancer Center — Philadelphia, Pennsylvania
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 2 Recruiting Industry
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06095505
Sites in Pennsylvania: - UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disea…
Sponsor: AbbVie
NCT ID: NCT06772623
Sites in Pennsylvania: - Spoknwrd Clinical Trials /ID# 273776 — Easton, Pennsylvania
Phase 2 Recruiting Industry
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combinati…
Sponsor: AstraZeneca
NCT ID: NCT05061550
Sites in Pennsylvania: - Research Site — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytological…
Sponsor: BioNTech SE
NCT ID: NCT07070232
Sites in Pennsylvania: - University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania